A Phase 2 interventional study of indocyanine green in Head and Neck Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Head and Neck Neoplasms with a site in Belgium — 18 open to participants now, 31 under way, 7 of them phase 3. Head and Neck Neoplasms · Belgium.
Among the 108 studies in Head and Neck Neoplasms with a site in Belgium, this one is the 65th largest by planned enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2020, is one of 28 in phase 2, reaches primary completion later than 11 of the 30 other live ones, and was the 82nd registered.
2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →18 of the 108 studies in Head and Neck Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
XEOS Medical · Sites in Belgium, Germany, Netherlands and 1 more country
Ages 18+
Bicara Therapeutics · Sites in Belgium, United States, Argentina and 25 more countries
Ages 18+
Inhibrx Biosciences, Inc · Sites in Belgium, United States, Australia and 10 more countries
Ages 18+
GlaxoSmithKline · Sites in Belgium, United States, Argentina and 28 more countries
Ages 18+
Daiichi Sankyo · Sites in Belgium, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 46 · Phase 3 27
First in 1994; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 65 is above the median of 46 across 2,036 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 123 across the 100 interventional studies, 72 across the 8 observational. Of the 70 that completed or were terminated, 28 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 108 have an industry lead sponsor. The 10 most frequent:
Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.
Gustave Roussy, Cancer Campus, Grand Paris has 7 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Head and Neck Neoplasms with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04842162Gustave Roussy, Cancer Campus, Grand ParisStudy Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery | 2026-11 |
| NCT04180371BicycleTx LimitedStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | 2026-12-31 |
| NCT06835426Algemeen Ziekenhuis Maria MiddelaresHigh-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins | 2027-01-30 |
| NCT04954599Maastricht University Medical CenterPhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | 2027-02 |
| NCT07431346Jules Bordet InstituteProphylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 108 studies in Head and Neck Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: indocyanine green
indocyanine green (INFRACYANINE© 25mg/10mL).
Sensitivity of Near Infrared Fluorescence Imaging
Sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after complete macroscopic surgical resection. For the calculation of the sensitivity, for each operating room we consider the first section and the last section in which the pathological analysis confirms the presence of microscopic residual disease. Patients for whom near-infrared fluorescence imaging detects disease are classified as true positives (TP). Sensitivity is defined as the number of TP divided by the total number of patients N.
Time frame: at surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for Nov 2026, 71 months after the start.
Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 71 months is above that.
Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Indocyanine Green
Gustave Roussy, Cancer Campus, Grand Paris →